+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Dalteparin"

Low Molecular Weight Heparin Global Market Report 2024 - Product Thumbnail Image

Low Molecular Weight Heparin Global Market Report 2024

  • Report
  • August 2024
  • 175 Pages
  • Global
From
Heparin Market Report 2025 - Product Thumbnail Image

Heparin Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
Anticoagulants Market Report 2025 - Product Thumbnail Image

Anticoagulants Market Report 2025

  • Report
  • January 2025
  • 200 Pages
  • Global
From
Deep Vein Thrombosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Thumbnail Image

Deep Vein Thrombosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • May 2024
  • 128 Pages
  • Global
From
Low Molecular Weight Heparin - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029) - Product Thumbnail Image

Low Molecular Weight Heparin - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029)

  • Report
  • July 2024
  • 110 Pages
  • Global
From
Middle East Low Molecular Weight Heparin Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product, Packaging, Application, End User and Distribution Channel - Product Thumbnail Image

Middle East Low Molecular Weight Heparin Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product, Packaging, Application, End User and Distribution Channel

  • Report
  • October 2022
  • 216 Pages
  • Middle East
From
Low Molecular Weight Heparin Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (Enoxaparin, Dalteparin, Tinzaparin, Fraxiparine, Nadroparin, and Others), Packaging (Multi-Vials and Prefilled Syringes), Application , and End User, and Geography - Product Thumbnail Image

Low Molecular Weight Heparin Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (Enoxaparin, Dalteparin, Tinzaparin, Fraxiparine, Nadroparin, and Others), Packaging (Multi-Vials and Prefilled Syringes), Application , and End User, and Geography

  • Report
  • December 2021
  • 191 Pages
  • Global
From
Heparin - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029 - Product Thumbnail Image

Heparin - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

  • Report
  • February 2024
  • 120 Pages
  • Global
From
Dalteparin Sodium Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Thumbnail Image

Dalteparin Sodium Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • January 2024
  • 111 Pages
  • Global
From
Low Molecular Weight Heparin Global Market Insights 2022, Analysis and Forecast to 2027, by Manufacturers, Regions, Technology, Application, Product Type - Product Thumbnail Image

Low Molecular Weight Heparin Global Market Insights 2022, Analysis and Forecast to 2027, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • August 2022
  • 87 Pages
  • Global
From
  • 10 Results (Page 1 of 1)
Loading Indicator

Dalteparin is a low molecular weight heparin (LMWH) anticoagulant used to prevent and treat thromboembolic disorders, including deep vein thrombosis (DVT) and pulmonary embolism (PE). It is also used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF). Dalteparin is administered subcutaneously and is available in a variety of dosage forms. Dalteparin is a widely used anticoagulant in the cardiovascular drugs market. It is used to prevent and treat thromboembolic disorders, reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, and to reduce the risk of recurrent myocardial infarction. It is also used to reduce the risk of death and recurrent myocardial infarction in patients with acute coronary syndrome. Some companies in the Dalteparin market include Sanofi, Pfizer, Bristol-Myers Squibb, and GlaxoSmithKline. Show Less Read more